|[January 31, 2013]
Alnylam to Webcast Conference Call Discussing Fourth Quarter and 2012 Financial Results
CAMBRIDGE, Mass. --(Business Wire)--
Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, today announced that it will report financial results for the
fourth quarter and year ending December 31, 2012, on Thursday, February
7, 2013, after the U.S. financial markets close.
Management will provide an update on the company, discuss fourth quarter
and year-end 2012 results, and discuss expectations for the future via
conference call on Thursday, February 7, 2013 at 4:30 p.m. ET. To access
the call, please dial 877-312-7507�(domestic) or
631-813-4828�(international) five minutes prior to the start time and
refer to conference ID 91074947. A replay of the call will be available
beginning at 7:30 p.m. ET on February 7, 2013. To access the replay,
please dial 855-859-2056�(domestic) or 404-537-3406�(international) and
refer to conference ID 91074947.
A live audio webcast of the call will also be available on the News &
Investors section of the company's website, www.alnylam.com.
An archived webcast will be available on the Alnylam website
approximately two hours after the event.
About Alnylam Pharmaceuticals
Alnylam is a biopharmaceutical company developing novel therapeutics
based on RNA interference, or RNAi. The company is leading the
translation of RNAi as a new class of innovative medicines with a core
focus on RNAi therapeutics for the treatment of genetically defined
diseases, including ALN-TTR for the treatment of transthyretin-mediated
amyloidosis (ATTR), ALN-AT3 for the treatment of hemophilia and rare
bleeding disorders (RBD), ALN-AS1 for the treatment of acute
intermittent porphyria, ALN-PCS for the treatment of
hypercholesterolemia, and ALN-TMP for the treatment of
hemoglobinopathies. As part of its "Alnylam 5x15TM" strategy,
the company expects to have five RNAi therapeutic products for
genetically defined diseases in clinical development, including programs
in advanced stages, on its own or with a partner by the end of 2015.
Alnylam has additional partnered programs in clinical or development
stages, including ALN-RSV01 for the treatment of respiratory syncytial
virus (RSV) infection and ALN-VSP for the treatment of liver cancers.
The company's leadership position on RNAi therapeutics and intellectual
property have enabled it to form major alliances with leading companies
including Merck, Medtronic, Novartis, Biogen Idec, Roche, Takeda, Kyowa
Hakko Kirin, Cubist, Ascletis, Monsanto, and Genzyme. In addition,
Alnylam holds a significant equity position in Regulus Therapeutics
Inc., a company focused on discovery, development, and commercialization
of microRNA therapeutics. Alnylam has also formed Alnylam
Biotherapeutics, a division of the company focused on the development of
RNAi technologies for applications in biologics manufacturing, including
recombinant proteins and monoclonal antibodies. Alnylam's VaxiRNA™
platform applies RNAi technology to improve the manufacturing processes
for vaccines; GlaxoSmithKline is a collaborator in this effort. Alnylam
scientists and collaborators have published their research on RNAi
therapeutics in over 100 peer-reviewed papers, including many in the
world's top scientific journals such as Nature, Nature Medicine,
Nature Biotechnology, and Cell. Founded in 2002, Alnylam
maintains headquarters in Cambridge, Massachusetts. For more
information, please visit www.alnylam.com.
[ InfoTech Spotlight's Homepage ]